Cytosorbents (CTSO) Shareholder's Equity Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.15% |
| Dec 31, 2025 | -44.95% |
| Sep 30, 2025 | -38.69% |
| Jun 30, 2025 | -37.55% |
| Mar 31, 2025 | -35.98% |
| Dec 31, 2024 | -43.80% |
| Sep 30, 2024 | -42.56% |
| Jun 30, 2024 | -38.35% |
| Mar 31, 2024 | -36.67% |
| Dec 31, 2023 | -33.33% |
| Sep 30, 2023 | -38.34% |
| Jun 30, 2023 | 0.19% |
| Mar 31, 2023 | 11.99% |
| Dec 31, 2022 | 117.92% |
| Sep 30, 2022 | 79.80% |
| Jun 30, 2022 | 60.32% |
| Mar 31, 2022 | 54.55% |
| Dec 31, 2021 | 54.60% |
| Sep 30, 2021 | 52.09% |
| Jun 30, 2021 | 51.10% |
| Mar 31, 2021 | 74.87% |
| Dec 31, 2020 | 97.63% |
| Sep 30, 2020 | 103.83% |
| Jun 30, 2020 | 45.38% |
| Mar 31, 2020 | 149.71% |
| Dec 31, 2019 | 36.72% |
| Sep 30, 2019 | 69.66% |
| Jun 30, 2019 | 43.61% |
| Mar 31, 2019 | 33.83% |
| Dec 31, 2018 | 19.81% |
| Dec 31, 2017 | 13.90% |
| Sep 30, 2017 | 42.23% |
| Jun 30, 2017 | 41.91% |
| Mar 31, 2017 | 39.97% |
| Dec 31, 2016 | 27.93% |
| Sep 30, 2016 | 28.08% |
| Jun 30, 2016 | 31.92% |
| Mar 31, 2016 | 36.17% |
| Dec 31, 2015 | 41.73% |
| Dec 31, 2014 | 39.05% |
| Sep 30, 2014 | -126.57% |
| Jun 30, 2014 | -89.58% |
| Dec 31, 2013 | -20.94% |